Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
Signal Transduction in the Blood-Brain Barriers
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults.
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Drak2 Does Not Regulate TGF-β Signaling in T Cells.
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients
Predictive value of early brain atrophy on response in patients treated with interferon β.
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Roche reports positive studies of MabThera given by subcutaneous injection
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Rituximab Use in Pediatric Central Demyelinating Disease.
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
Treatment of acute transverse myelitis and its early complications.

Pages